ORCID
- Jeremy Hobart: 0000-0002-2114-7920
DOI Link
Publication Date
2020-07-24
Publication Title
CNS Drugs
ISSN
1172-7047
Acceptance Date
2020-06-17
Embargo Period
2020-08-11
Recommended Citation
Ziemssen, T., Bass, A., Berkovich, R., Comi, G., Eichau, S., Hobart, J., Hunter, S., LaGanke, C., Limmroth, V., Pelletier, D., Pozzilli, C., Schippling, S., Sousa, L., Traboulsee, A., Uitdehaag, B., Van, W., Choudhry, Z., Daizadeh, N., & Singer, B. (2020) 'Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study', CNS Drugs, . Available at: 10.1007/s40263-020-00749-x
